 SpringWorks Therapeutics Inc NASDAQ: SWTX has dosed the first patient in a Phase 1b clinical trial evaluating nirogacestat combined with Johnson Johnsons NYSE: JNJJanssens teclistamab in patients with relapsed or refractory multiple myeloma. Nirogacestat is an investigational gamma-secretase inhibitor GSI developed by SpringWorks. 